NetworkNewsBreaks — Longeveron Inc. (NASDAQ: LGV
Post# of 50
(Total Views: 237)
Posted On: 09/07/2023 4:15:45 PM
NetworkNewsBreaks — Longeveron Inc. (NASDAQ: LGVN; LGVNR) Announces ELPIS 1 Trial Data Accepted for AHA Presentation, IBN Partnership
Longeveron (NASDAQ: LGVN; LGVNR), a clinical-stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions such as hypoplastic left heart syndrome (“HLHS”), Alzheimer’s disease and Aging-Related Frailty, will be participating at the American Heart Association Scientific Sessions. The company announced that an abstract outlining long-term survival data from its ELPIS 1 trial of Lomecel-B(TM) for patients with HLHS has been accepted for presentation as a poster at upcoming Scientific Sessions. The sessions are slated to be held Nov. 11–13, 2023, in Philadelphia. The poster is titled “Long-Term Transplant-Free Survival Is Improved in Hypoplastic Left Heart Syndrome with Cell-Based Therapy.” The long-term survival data from the ELPIS 1 trial indicates that children in the trial had 100% survival up to five years of age after receiving Lomecel-B(TM) compared to 20% mortality rate observed from historical control data.
In addition, Longeveron announced that it is partnering with IBN, a multifaceted financial news and publishing company for private and public entities, to assist with its investor communications. According to the announcement, IBN will leverage its investor-based distribution network of 5,000+ key syndication outlets, numerous newsletters, social media channels, wire services via InvestorWire, blogs and other outreach tools to strengthen and increase industry awareness for Longeveron. Longeveron’s lead investigational product is Lomecel-B. Data has shown that the product may be effective in dealing with a decrease in immune system function that occurs as humans age as well as a decline in blood vessel functioning, chronic inflammation and other issues. “While there has been a remarkable rise in life expectancy over the last century due to medical and public health advancements, this increase in longevity has not been paralleled by the number of years a person is expected to live in relatively good health, free of chronic disease and disabilities of aging,” said IBN director of operations Chris Johnson in the press release. “We’re excited to customize our comprehensive suite of corporate communications solutions for Longeveron as it works to address this unmet medical need through its clinical pipeline, including the expected release of top-line results from its phase 2a CLEAR MIND trial of Lomecel-B for the treatment of Alzheimer’s disease in the coming weeks.”
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Longeveron (NASDAQ: LGVN; LGVNR), a clinical-stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions such as hypoplastic left heart syndrome (“HLHS”), Alzheimer’s disease and Aging-Related Frailty, will be participating at the American Heart Association Scientific Sessions. The company announced that an abstract outlining long-term survival data from its ELPIS 1 trial of Lomecel-B(TM) for patients with HLHS has been accepted for presentation as a poster at upcoming Scientific Sessions. The sessions are slated to be held Nov. 11–13, 2023, in Philadelphia. The poster is titled “Long-Term Transplant-Free Survival Is Improved in Hypoplastic Left Heart Syndrome with Cell-Based Therapy.” The long-term survival data from the ELPIS 1 trial indicates that children in the trial had 100% survival up to five years of age after receiving Lomecel-B(TM) compared to 20% mortality rate observed from historical control data.
In addition, Longeveron announced that it is partnering with IBN, a multifaceted financial news and publishing company for private and public entities, to assist with its investor communications. According to the announcement, IBN will leverage its investor-based distribution network of 5,000+ key syndication outlets, numerous newsletters, social media channels, wire services via InvestorWire, blogs and other outreach tools to strengthen and increase industry awareness for Longeveron. Longeveron’s lead investigational product is Lomecel-B. Data has shown that the product may be effective in dealing with a decrease in immune system function that occurs as humans age as well as a decline in blood vessel functioning, chronic inflammation and other issues. “While there has been a remarkable rise in life expectancy over the last century due to medical and public health advancements, this increase in longevity has not been paralleled by the number of years a person is expected to live in relatively good health, free of chronic disease and disabilities of aging,” said IBN director of operations Chris Johnson in the press release. “We’re excited to customize our comprehensive suite of corporate communications solutions for Longeveron as it works to address this unmet medical need through its clinical pipeline, including the expected release of top-line results from its phase 2a CLEAR MIND trial of Lomecel-B for the treatment of Alzheimer’s disease in the coming weeks.”
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)